Anti-integrin portfolio

Allegro has announced the expansion of the company’s anti-integrin portfolio

Anti-integrin portfolio
Colin Kerr
Colin Kerr
Published: Saturday, June 1, 2019
Allegro Ophthalmics has announced the expansion of the company’s anti-integrin portfolio with ALG-1007, a topical treatment in development for potential use in patients with dry eye disease (DED). ALG-1007 bolsters Allegro’s existing anti-integrin portfolio, which includes risuteganib (Luminate®), currently being developed for diabetic macular oedema (DME) and intermediate dry age-related macular degeneration (AMD). Allegro has also announced that Richard L. Lindstrom MD, Edward J. Holland MD and Eric D. Donnenfeld MD, have joined the company’s newly formed Cornea Scientific Advisory Board (Cornea SAB) to provide strategy and direction on Allegro’s clinical development pipeline in the areas of corneal disease and dry eye. Dr Lindstrom will serve as Chairperson of the Cornea SAB. https://www.allegroeye.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...